Language Selector

    TRANSVAC: Open Call for Vaccine Development Services in Europe

    Published on 01 March 2018
    Author: Nicole Wyss, National Contact Point Research Infrastructures

    TRANSVAC is a collaborative infrastructure project, designed to accelerate vaccine development. The next deadline for applications for services and access is 15 April 2018.

    TRANSVAC is a new infrastructure project - funded by the European Commission in the context of Horizon 2020 - that aims to accelerate the development of effective vaccines urgently needed to address European and global health challenges with the ultimate goal to build an efficient and sustainable collaboration of experts and facilities to catalyse vaccine research in Europe.

    TRANSVAC will offer high-quality technical services to support the development of prophylactic and therapeutic vaccines for both human and animal use. These services are not restricted to any disease in particular. Except for the few cases indicated on the website, services will be offered free of charge! Academic and non-academic research groups, SMEs and industries can apply but only to service infrastructures outside their own country.

    The call for application was launched on 15 October 2017 and will remain open for the duration of the project (until April 2022) or until all services have been exhausted. Applications can be submitted at any time as soon as the application form for the next cut-off date is online and will be processed at pre-defined cut-off dates occurring every four months. The second cut-off date is on 15 April 2018. Users of the services will be selected via an independent scientific peer review process. The selected projects will then be able to commence work within TRANSVAC shortly after notification.

    For more information about the services offered by TRANSVAC, the eligibility criteria and the application process, as well as to download the application form, please visit www.transvac.org.
    If you have any specific questions, you can contact the project management team at:
    transvacinfo@euvaccine.eu